<p>Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）- HC Wainwright 的股票研究分析師在 11 月 13 日星期四發佈的報告中下調了 Journey Medical 2025 財年的每股收益（EPS）預期。HC Wainwright 的分析師 B. Folkes 現在預測該公司將發佈每股收益（$0.53），低於之前的預期（$0.45）。HC Wainwright 目前對該股票的評級為 “買入”，目標價為 13.00 美元。市場普遍預期 Journey Medical 當前全年的每股收益為（$1.02）。HC Wainwright 還對 Journey Medical 2025 年第四季度的每股收益預期為（$0.10）。</p>
<p>其他幾家券商也對 DERM 發表了看法。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Journey Medical 股票的 “賣出（d-）” 評級。Zacks Research 在 10 月 13 日星期一的報告中將 Journey Medical 的評級從 “強烈賣出” 上調至 “持有”。最後，Lake Street Capital 在 8 月 13 日星期三的研究報告中將 Journey Medical 的目標價從 9.00 美元上調至 13.00 美元，並給予該股票 “買入” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為 12.17 美元。</p>
<p>獲取 <strong>Journey Medical</strong> 的提醒：</p>
<p><strong>查看我們對 Journey Medical 的最新股票分析</strong></p>
<h2>Journey Medical 股票表現</h2>
<p>納斯達克 DERM 週一開盤價為 7.89 美元。該股票的 50 日簡單移動平均線為 7.65 美元，200 日簡單移動平均線為 7.32 美元。該公司的流動比率為 1.42，速動比率為 1.12，債務與股本比率為 0.75。該股票的市值為 2.0759 億美元，市盈率為 -22.54，貝塔值為 0.80。Journey Medical 的 12 個月低點為 3.54 美元，12 個月高點為 9.40 美元。</p>
<p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近在 11 月 12 日星期三發佈了季度財報。該公司報告的每股收益為（$0.09），低於市場共識預期的（$0.08）$0.01。Journey Medical 的股本回報率為 -39.94%，淨利潤率為 -14.58%。該業務在本季度的收入為 1763 萬美元，而分析師的預期為 1885 萬美元。</p>
<h2>Journey Medical 的機構交易</h2>
<p>一些大型投資者最近對 DERM 的持倉進行了調整。Wasatch Advisors LP 在第二季度將其在 Journey Medical 的持股增加了 23.8%。Wasatch Advisors LP 目前擁有 1,152,059 股該公司的股票，價值 8,272,000 美元，此前在上個季度增持了 221,456 股。Geode Capital Management LLC 在第二季度將其在 Journey Medical 的持股增加了 130.7%。Geode Capital Management LLC 目前擁有 262,353 股該公司的股票，價值 1,884,000 美元，此前在上個季度增持了 148,612 股。Sheets Smith Investment Management 在第三季度購買了 Journey Medical 的新股份，價值 946,000 美元。Essex Investment Management Co. LLC 在第三季度將其在 Journey Medical 的持股增加了 55.1%。Essex Investment Management Co. LLC 目前擁有 354,021 股該公司的股票，價值 2,521,000 美元，此前在上個季度增持了 125,818 股。最後，Vanguard Group Inc. 在第三季度將其在 Journey Medical 的持股增加了 8.9%。Vanguard Group Inc. 目前擁有 615,229 股該公司的股票，價值 4,380,000 美元，此前在上個季度增持了 50,241 股。7.25% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>關於 Journey Medical</h2>
<p>（獲取免費報告）</p>
<p>Journey Medical Corporation 專注於開發和商業化用於治療美國皮膚病的藥品。該公司的市場產品包括 Qbrexza，一種用於治療原發性腋下多汗症的藥用濕巾；Accutane，一種用於治療嚴重頑固性結節性痤瘡的口服異維 A 酸藥物；以及 Amzeeq，一種用於治療中度至重度非結節性痤瘡炎症病變的米諾環素外用製劑。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Journey Medical</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>4 只適合冬季消費的冷天氣股票</li>
<li>什麼是內幕交易？你可以從內幕交易中學到什麼</li>
<li>Disney 股票下跌——收益是否為 YouTube TV 和解鋪平道路？</li>
<li>投資者需要了解即將上市的 IPO</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Journey Medical 嗎？</h2>
<p>在考慮 Journey Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Journey Medical 並不在名單上。</p>
<p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DERM

<p>HC Wainwright 已將 Journey Medical 的 2025 財年每股收益預測從 ($0.45) 下調至 ($0.53)，維持 “買入” 評級，目標價為 $13.00。該股票在分析師中獲得了混合評級，普遍評級為 “持有”，平均目標價為 $12.17。Journey Medical 最近的季度收益未能達到預期，股票在納斯達克開盤價為 $7.89。機構投資者正在調整在該公司的持倉</p>

<p>Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 EPS estimates for shares of Journey Medical in a report released on Thursday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.53) per share for the year, down from their previous estimate of ($0.45). HC Wainwright currently has a &#34;Buy&#34; rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q4 2025 earnings at ($0.10) EPS.</p>
<div class="lb-trans"><p>Journey Medical Corporation（納斯達克代碼：DERM - 免費報告）- HC Wainwright 的股票研究分析師在 11 月 13 日星期四發佈的報告中下調了 Journey Medical 2025 財年的每股收益（EPS）預期。HC Wainwright 的分析師 B. Folkes 現在預測該公司將發佈每股收益（$0.53），低於之前的預期（$0.45）。HC Wainwright 目前對該股票的評級為 “買入”，目標價為 13.00 美元。市場普遍預期 Journey Medical 當前全年的每股收益為（$1.02）。HC Wainwright 還對 Journey Medical 2025 年第四季度的每股收益預期為（$0.10）。</p>
</div><p>Several other brokerages have also weighed in on DERM. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Journey Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Finally, Lake Street Capital upped their price target on Journey Medical from $9.00 to $13.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $12.17.</p>
<div class="lb-trans"><p>其他幾家券商也對 DERM 發表了看法。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Journey Medical 股票的 “賣出（d-）” 評級。Zacks Research 在 10 月 13 日星期一的報告中將 Journey Medical 的評級從 “強烈賣出” 上調至 “持有”。最後，Lake Street Capital 在 8 月 13 日星期三的研究報告中將 Journey Medical 的目標價從 9.00 美元上調至 13.00 美元，並給予該股票 “買入” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為 12.17 美元。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Journey Medical</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on Journey Medical</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Journey Medical 的最新股票分析</strong></p>
</div><h2>Journey Medical Stock Performance</h2>
<div class="lb-trans"><h2>Journey Medical 股票表現</h2>
</div><p>NASDAQ DERM opened at $7.89 on Monday. The stock has a fifty day simple moving average of $7.65 and a 200-day simple moving average of $7.32. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75. The stock has a market cap of $207.59 million, a PE ratio of -22.54 and a beta of 0.80. Journey Medical has a twelve month low of $3.54 and a twelve month high of $9.40.</p>
<div class="lb-trans"><p>納斯達克 DERM 週一開盤價為 7.89 美元。該股票的 50 日簡單移動平均線為 7.65 美元，200 日簡單移動平均線為 7.32 美元。該公司的流動比率為 1.42，速動比率為 1.12，債務與股本比率為 0.75。該股票的市值為 2.0759 億美元，市盈率為 -22.54，貝塔值為 0.80。Journey Medical 的 12 個月低點為 3.54 美元，12 個月高點為 9.40 美元。</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Journey Medical had a negative return on equity of 39.94% and a negative net margin of 14.58%.The business had revenue of $17.63 million during the quarter, compared to analysts' expectations of $18.85 million.</p>
<div class="lb-trans"><p>Journey Medical（納斯達克代碼：DERM - 獲取免費報告）最近在 11 月 12 日星期三發佈了季度財報。該公司報告的每股收益為（$0.09），低於市場共識預期的（$0.08）$0.01。Journey Medical 的股本回報率為 -39.94%，淨利潤率為 -14.58%。該業務在本季度的收入為 1763 萬美元，而分析師的預期為 1885 萬美元。</p>
</div><h2>Institutional Trading of Journey Medical</h2>
<div class="lb-trans"><h2>Journey Medical 的機構交易</h2>
</div><p>A number of large investors have recently made changes to their positions in DERM. Wasatch Advisors LP raised its holdings in Journey Medical by 23.8% in the second quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock valued at $8,272,000 after acquiring an additional 221,456 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Journey Medical by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock valued at $1,884,000 after purchasing an additional 148,612 shares in the last quarter. Sheets Smith Investment Management purchased a new stake in shares of Journey Medical during the 3rd quarter worth $946,000. Essex Investment Management Co. LLC lifted its position in shares of Journey Medical by 55.1% during the 3rd quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company's stock worth $2,521,000 after purchasing an additional 125,818 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Journey Medical by 8.9% during the third quarter. Vanguard Group Inc. now owns 615,229 shares of the company's stock worth $4,380,000 after purchasing an additional 50,241 shares in the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近對 DERM 的持倉進行了調整。Wasatch Advisors LP 在第二季度將其在 Journey Medical 的持股增加了 23.8%。Wasatch Advisors LP 目前擁有 1,152,059 股該公司的股票，價值 8,272,000 美元，此前在上個季度增持了 221,456 股。Geode Capital Management LLC 在第二季度將其在 Journey Medical 的持股增加了 130.7%。Geode Capital Management LLC 目前擁有 262,353 股該公司的股票，價值 1,884,000 美元，此前在上個季度增持了 148,612 股。Sheets Smith Investment Management 在第三季度購買了 Journey Medical 的新股份，價值 946,000 美元。Essex Investment Management Co. LLC 在第三季度將其在 Journey Medical 的持股增加了 55.1%。Essex Investment Management Co. LLC 目前擁有 354,021 股該公司的股票，價值 2,521,000 美元，此前在上個季度增持了 125,818 股。最後，Vanguard Group Inc. 在第三季度將其在 Journey Medical 的持股增加了 8.9%。Vanguard Group Inc. 目前擁有 615,229 股該公司的股票，價值 4,380,000 美元，此前在上個季度增持了 50,241 股。7.25% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>About Journey Medical</h2>
<div class="lb-trans"><h2>關於 Journey Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</p>
<div class="lb-trans"><p>Journey Medical Corporation 專注於開發和商業化用於治療美國皮膚病的藥品。該公司的市場產品包括 Qbrexza，一種用於治療原發性腋下多汗症的藥用濕巾；Accutane，一種用於治療嚴重頑固性結節性痤瘡的口服異維 A 酸藥物；以及 Amzeeq，一種用於治療中度至重度非結節性痤瘡炎症病變的米諾環素外用製劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Journey Medical</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>4 只適合冬季消費的冷天氣股票</li>
<li>什麼是內幕交易？你可以從內幕交易中學到什麼</li>
<li>Disney 股票下跌——收益是否為 YouTube TV 和解鋪平道路？</li>
<li>投資者需要了解即將上市的 IPO</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Journey Medical 嗎？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Journey Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Journey Medical 並不在名單上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Journey Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

分析師下調了 Journey Medical 的 2025 財年每股收益預測